A carregar...
Chronic ischaemic heart disease and rivaroxaban: which patients derive the greatest benefit?
Patients with established cardiovascular (CV) disease may suffer further CV events, despite receiving optimal medical treatment. Although platelet inhibition plays a central role in the prevention of new events, the use of anticoagulant therapies to reduce events in atheromatous disease has, until r...
Na minha lista:
| Publicado no: | Eur Heart J Suppl |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7673606/ https://ncbi.nlm.nih.gov/pubmed/33239976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/suaa128 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|